Solely within the frenzied metabolic drug business may a 32% gross sales progress be thought-about a disappointment. That's how a lot Eli Lilly's income grew in 2024, however it nonetheless wasn't as a lot as the corporate or buyers anticipated, prompting CEO David Ricks to attempt to calm buyers. Lilly on Tuesday revised its fourth-quarter income steerage to about $13.5 […]
